Cargando…

Challenges of predicting immune checkpoint therapy responders in lung cancer

Detalles Bibliográficos
Autor principal:	Marwitz, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797686/ https://www.ncbi.nlm.nih.gov/pubmed/35116808 http://dx.doi.org/10.21037/tcr.2019.04.07

Ejemplares similares

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
por: Vryza, Paraskevi, et al.
Publicado: (2023)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Increased abscopal responses after radiation therapy for oligoprogressive patients receiving immune checkpoint inhibitors?
por: Doyen, Jérôme, et al.
Publicado: (2023)

Management of immune checkpoint therapy for patients with cancer in the face of COVID-19
por: Shen, Chen, et al.
Publicado: (2020)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
por: Marwitz, Sebastian, et al.
Publicado: (2017)

Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
por: Mukherjee, Sandeep
Publicado: (2023)

CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy
por: Jain, Swati, et al.
Publicado: (2023)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
por: Lerrer, Shalom, et al.
Publicado: (2019)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease
por: Chau, Charlene Y. C., et al.
Publicado: (2020)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors
por: Arasanz, Hugo, et al.
Publicado: (2023)

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
por: Nishino, Mizuki
Publicado: (2016)

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
por: Wongariyapak, Amarin, et al.
Publicado: (2023)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Thoracoscopic anatomical segmentectomies for early-stage lung cancer: the coming challenge
por: Gossot, Dominique, et al.
Publicado: (2020)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_td49uv8ttbic2qsfo9dc47b4rl